QNTM earnings: next report 2026-08-06, real EPS beat/miss history, P/E -0.35. Updated 2026-07-23.
Quantum BioPharma (QNTM) Research Hub
Quantum BioPharma (QNTM) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.2 USD (-10.61%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.35, market cap 0.01B. This hub links to the full technical, earnings and options research available for QNTM.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 3.2 USD (-10.61%) |
| 52-week range | 2.66 USD – 4.4 USD |
| Trend regime | Range |
| 14-day RSI | 45.2 (Neutral) |
| Trailing P/E | -0.35 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for QNTM
Covered Call on QNTM: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on QNTM: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on QNTM: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
QNTM technical analysis: range, last 3.2 USD, RSI 45.2, 52w range 2.66 USD–4.4 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is QNTM in?
Quantum BioPharma (QNTM) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is QNTM in an uptrend or downtrend?
As of 2026-09-11, QNTM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is QNTM's trailing P/E ratio?
QNTM's trailing P/E is -0.35, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does QNTM next report earnings?
QNTM is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.4116 USD.